
Ra Medical Systems RMED
Annual report 2025
added 03-31-2026
Ra Medical Systems Book Value 2011-2026 | RMED
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Ra Medical Systems
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.65 M | 11.8 M | 9.26 M | 13.7 M | 21.1 M | 33.2 M | 66.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 66.7 M | 6.65 M | 23.2 M |
Quarterly Book Value Ra Medical Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.45 M | 6.55 M | 7.92 M | 11.8 M | - | 14.3 M | 18.5 M | 21.2 M | 21.9 M | 23.8 M | 35.9 M | 9.26 M | 12.5 M | 9.79 M | 18.1 M | 13.7 M | 21.5 M | 21.3 M | 15.1 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 66.7 M | 66.7 M | 66.7 M | 66.7 M | -7.62 M | -7.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 66.7 M | -7.62 M | 23.7 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 62.59 | -0.37 % | $ 92.7 B | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.07 | 0.33 % | $ 1.63 B | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.59 | 1.2 % | $ 36.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Delcath Systems
DCTH
|
111 M | $ 9.7 | 0.73 % | $ 347 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
EDAP TMS S.A.
EDAP
|
56.9 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 81.19 | 0.17 % | $ 47.5 B | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.6 | 0.05 % | $ 122 M | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.13 | 0.49 % | $ 874 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 36.74 | -0.05 % | $ 5.47 K | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
AxoGen
AXGN
|
129 M | $ 32.64 | -5.23 % | $ 1.5 B | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.9 | 2.15 % | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 9.31 | -2.31 % | $ 717 M | ||
|
Inogen
INGN
|
192 M | $ 6.36 | 2.42 % | $ 169 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.0 | 1.66 % | $ 16.9 M | ||
|
IRadimed Corporation
IRMD
|
94.6 M | $ 95.66 | -0.59 % | $ 1.22 B | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 85.63 | -1.4 % | $ 2.97 B | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Align Technology
ALGN
|
3.85 B | $ 171.87 | 0.74 % | $ 12.9 B | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 15.94 | -0.75 % | $ 374 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.89 | -2.81 % | $ 70.4 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 9.38 | 0.11 % | $ 266 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.36 | 2.26 % | $ 55.3 M | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Medtronic PLC
MDT
|
48.3 B | $ 86.28 | -0.4 % | $ 111 B | ||
|
MiMedx Group
MDXG
|
257 M | $ 3.88 | -1.02 % | $ 573 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
Myomo
MYO
|
11.4 M | $ 0.7 | 4.84 % | $ 29.3 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Orthofix Medical
OFIX
|
450 M | $ 11.77 | 2.08 % | $ 466 M | ||
|
PAVmed
PAVM
|
22.3 M | $ 10.04 | 1.93 % | $ 6.73 M |